Clinical Trial Update: Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating neoadjuvant SBRT with tislelizumab and anlotinib for resectable EGFR wild-type non-small cell lung cancer; the trial is not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Neoadjuvant Immunotherapy, NSCLC | Phase 2 | Status: NOT_YET_RECRUITING